Peter Hoogerbrugge
0000-0003-3012-6109
2 papers found
Refreshing results…
Improved Outcome for ALL by Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for Other Risk Groups
Anti-GD2 antibody and Vorinostat immunocombination therapy is highly effective in an aggressive orthotopic neuroblastoma model
Missing publications? Search for publications with a matching author name.